$11.13
+0.03 (+0.27%)
Last updated: Apr 16, 2026 02:38
Fundamentals Overview
Verve Therapeutics, Inc. is in the middle of its 52-week range with premium valuation, trading relatively flat today.
Valuation premium
Intrinsic value (DCF)
-80.3% downside vs price
Risk (Beta)
2.24 — higher vol
BullzEye Analysis
Our composite tilts Sell on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Pressures (Sell):
DCF 80.3% downside vs price · Sentiment weakening (6 downgrades) · Beta 2.24 (elevated)
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Recent institutional grades: majority downgrades. Current institutional positions: Buy: 14, Hold: 2, Market Perform: 3, Neutral: 5, Outperform: 5, Overweight: 1.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $2.19; current price is $11.13. That’s a -80.3% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | N/A |
| DCF value (model) | $2.19 (-80.3% vs price) |
| PEG (TTM) | N/A |
| P/B (TTM) | 2.09 |
| P/S (TTM) | 21.58 |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 9.84 |
| Quick Ratio (TTM) | 9.84 |
| Cash Ratio (TTM) | 1.86 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | -1.76% |
| Gross margin (TTM) | 100% |
| Operating margin (TTM) | -2.01% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for VERV.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| BMO Capital | downgrade | Outperform | Market Perform | 2025-06-27 |
| LifeSci Capital | downgrade | Outperform | Market Perform | 2025-06-18 |
| Jefferies | downgrade | Buy | Hold | 2025-06-18 |
| HC Wainwright & Co. | downgrade | Buy | Neutral | 2025-06-18 |
| William Blair | downgrade | Outperform | Market Perform | 2025-06-17 |
| Canaccord Genuity | downgrade | Buy | Hold | 2025-06-17 |
| Guggenheim | maintain | Buy | Buy | 2025-04-15 |
| Cantor Fitzgerald | upgrade | Neutral | Overweight | 2025-04-15 |
| Canaccord Genuity | maintain | Buy | Buy | 2025-04-15 |
| William Blair | maintain | Outperform | Outperform | 2025-04-15 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-04-14 |
| Guggenheim | maintain | Buy | Buy | 2025-03-25 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-03-25 |
| RBC Capital | maintain | Outperform | Outperform | 2025-03-04 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-02-28 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2024-11-06 |
| Canaccord Genuity | maintain | Buy | Buy | 2024-11-06 |
| RBC Capital | maintain | Outperform | Outperform | 2024-11-06 |
| Canaccord Genuity | maintain | Buy | Buy | 2024-08-12 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2024-08-12 |
| RBC Capital | maintain | Outperform | Outperform | 2024-08-09 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2024-05-09 |
| Stifel | maintain | Buy | Buy | 2024-04-03 |
| RBC Capital | maintain | Outperform | Outperform | 2024-02-28 |
| Cantor Fitzgerald | maintain | Neutral | Neutral | 2023-09-13 |
| Cantor Fitzgerald | maintain | Neutral | Neutral | 2023-09-12 |
| Cantor Fitzgerald | maintain | Neutral | Neutral | 2023-08-29 |
| Cantor Fitzgerald | maintain | Neutral | Neutral | 2023-08-28 |
| Guggenheim | maintain | Buy | Buy | 2023-08-15 |
| Guggenheim | maintain | Buy | Buy | 2023-08-14 |